Prognostic value and predictive model of tumor markers in stage I to III gastric cancer patients

Table 3 Univariate and multivariate cox regression analysis for overall survival

Variables	OS
	HR (95%CI)	P value
Univariate analysis
Gender (male vs female)	0.922 (0.729-1.165)	0.496
Age (< 65 vs ≥ 65)	1.315 (1.080-1.604)	0.007
Clinical stage
I	1 (Reference)
II	2.876 (1.735-4.768)	0.000
III	8.712 (5.601-13.552)	0.000
T stage
T1	1 (Reference)
T2	1.693 (0.889-3.227)	0.019
T3	4.438 (2.634-7.478)	0.000
T4	6.330 (3.981-10.065)	0.000
N stage
N0	1 (Reference)
N1	2.330 (1.667-3.257)	0.000
N2	3.239 (2.383-4.401)	0.000
N3	5.201 (3.957-6.836)	0.000
Location
Cardia	1 (Reference)
Gastric body	1.306 (1.025-1.664)	0.031
Antrum of stomach	1.698 (1.276-2.261)	0.000
Pathological type (adenocarcinoma vs other)	1.209 (0.807-1.813)	0.358
Differentiation (well, high and medium vs moderate to low and poor)	1.776 (1.392-2.265)	0.000
Borrmann type (III vs other)	0.579 (0.462-0.724)	0.000
Size (< 5 vs ≥ 5)	0.403 (0.329-0.494)	0.000
AFP (positive vs negative)	1.929 (1.520-2.448)	0.000
CEA (positive vs negative)	3.155 (2.584-3.851)	0.000
CA125 (positive vs negative)	2.521 (2.067-3.074)	0.000
CA19-9 (positive vs negative)	3.489 (2.847-4.276)	0.000
Multivariate analysis
Age (< 65 vs ≥ 65)	1.225 (0.999-1.501)	0.052
Clinical stage
I	1 (Reference)
II	2.102 (1.248-3.540)	0.005
III	4.860 (2.988-7.907)	0.000
Location
Cardia	1 (Reference)
Gastric body	1.531 (1.187-1.976)	0.051
Antrum of stomach	1.092 (0.847-1.406)	0.498
Differentiation (well, high and medium vs moderate to low and poor)	1.212 (0.940-1.564)	0.139
Borrmann type (III vs other)	0.873 (0.688-1.108)	0.265
Size (< 5 vs ≥ 5)	1.269 (1.020-1.578)	0.032
AFP (positive vs negative)	1.728 (1.359-2.198)	0.000
CEA (positive vs negative)	2.037 (1.646-2.522)	0.000
CA125 (positive vs negative)	1.739 (1.416-2.135)	0.000
CA19-9 (positive vs negative)	1.910 (1.535-2.377)	0.000

OS: Overall survival; HR: Hazard ratio.